GlassScriptPhysician profile
Taylor Hall
NPI 1558939991
$1,126.15
in general payments reported to CMS, 2019-2025
17 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $335 · 2023: $378 · 2024: $145 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $156.75 | 2022-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $137.06 | 2022-2023 | Austedo |
| Neurocrine Biosciences, INC. | $128.07 | 2022-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $125.03 | 2023-2025 | Auvelity |
| Abbvie INC. | $91.40 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.02 | 2022-2025 | Trintellix |
| Tris Pharma INC | $72.23 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $54.17 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.24 | 2022-2025 | Caplyta |
| Noven Therapeutics, LLC | $50.06 | 2024-2025 | Xelstrym |
| Janssen Pharmaceuticals, INC | $40.47 | 2022-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $32.82 | 2023-2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $27.08 | 2023 | Aristada, Lybalvi |
| Bausch Health US, LLC | $21.06 | 2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $20.61 | 2025 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $15.58 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.50 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.